Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

dc.contributor.author

Ware, Russell E

dc.contributor.author

Davis, Barry R

dc.contributor.author

Schultz, William H

dc.contributor.author

Brown, R Clark

dc.contributor.author

Aygun, Banu

dc.contributor.author

Sarnaik, Sharada

dc.contributor.author

Odame, Isaac

dc.contributor.author

Fuh, Beng

dc.contributor.author

George, Alex

dc.contributor.author

Owen, William

dc.contributor.author

Luchtman-Jones, Lori

dc.contributor.author

Rogers, Zora R

dc.contributor.author

Hilliard, Lee

dc.contributor.author

Gauger, Cynthia

dc.contributor.author

Piccone, Connie

dc.contributor.author

Lee, Margaret T

dc.contributor.author

Kwiatkowski, Janet L

dc.contributor.author

Jackson, Sherron

dc.contributor.author

Miller, Scott T

dc.contributor.author

Roberts, Carla

dc.contributor.author

Heeney, Matthew M

dc.contributor.author

Kalfa, Theodosia A

dc.contributor.author

Nelson, Stephen

dc.contributor.author

Imran, Hamayun

dc.contributor.author

Nottage, Kerri

dc.contributor.author

Alvarez, Ofelia

dc.contributor.author

Rhodes, Melissa

dc.contributor.author

Thompson, Alexis A

dc.contributor.author

Rothman, Jennifer A

dc.contributor.author

Helton, Kathleen J

dc.contributor.author

Roberts, Donna

dc.contributor.author

Coleman, Jamie

dc.contributor.author

Bonner, Melanie J

dc.contributor.author

Kutlar, Abdullah

dc.contributor.author

Patel, Niren

dc.contributor.author

Wood, John

dc.contributor.author

Piller, Linda

dc.contributor.author

Wei, Peng

dc.contributor.author

Luden, Judy

dc.contributor.author

Mortier, Nicole A

dc.contributor.author

Stuber, Susan E

dc.contributor.author

Luban, Naomi LC

dc.contributor.author

Cohen, Alan R

dc.contributor.author

Pressel, Sara

dc.contributor.author

Adams, Robert J

dc.coverage.spatial

England

dc.date.accessioned

2018-02-01T14:22:57Z

dc.date.available

2018-02-01T14:22:57Z

dc.date.issued

2016-02-13

dc.description.abstract

BACKGROUND: For children with sickle cell anaemia and high transcranial doppler (TCD) flow velocities, regular blood transfusions can effectively prevent primary stroke, but must be continued indefinitely. The efficacy of hydroxycarbamide (hydroxyurea) in this setting is unknown; we performed the TWiTCH trial to compare hydroxyurea with standard transfusions. METHODS: TWiTCH was a multicentre, phase 3, randomised, open-label, non-inferiority trial done at 26 paediatric hospitals and health centres in the USA and Canada. We enrolled children with sickle cell anaemia who were aged 4-16 years and had abnormal TCD flow velocities (≥ 200 cm/s) but no severe vasculopathy. After screening, eligible participants were randomly assigned 1:1 to continue standard transfusions (standard group) or hydroxycarbamide (alternative group). Randomisation was done at a central site, stratified by site with a block size of four, and an adaptive randomisation scheme was used to balance the covariates of baseline age and TCD velocity. The study was open-label, but TCD examinations were read centrally by observers masked to treatment assignment and previous TCD results. Participants assigned to standard treatment continued to receive monthly transfusions to maintain 30% sickle haemoglobin or lower, while those assigned to the alternative treatment started oral hydroxycarbamide at 20 mg/kg per day, which was escalated to each participant's maximum tolerated dose. The treatment period lasted 24 months from randomisation. The primary study endpoint was the 24 month TCD velocity calculated from a general linear mixed model, with the non-inferiority margin set at 15 cm/s. The primary analysis was done in the intention-to-treat population and safety was assessed in all patients who received at least one dose of assigned treatment. This study is registered with ClinicalTrials.gov, number NCT01425307. FINDINGS: Between Sept 20, 2011, and April 17, 2013, 159 patients consented and enrolled in TWiTCH. 121 participants passed screening and were then randomly assigned to treatment (61 to transfusions and 60 to hydroxycarbamide). At the first scheduled interim analysis, non-inferiority was shown and the sponsor terminated the study. Final model-based TCD velocities were 143 cm/s (95% CI 140-146) in children who received standard transfusions and 138 cm/s (135-142) in those who received hydroxycarbamide, with a difference of 4·54 (0·10-8·98). Non-inferiority (p=8·82 × 10(-16)) and post-hoc superiority (p=0·023) were met. Of 29 new neurological events adjudicated centrally by masked reviewers, no strokes were identified, but three transient ischaemic attacks occurred in each group. Magnetic resonance brain imaging and angiography (MRI and MRA) at exit showed no new cerebral infarcts in either treatment group, but worsened vasculopathy in one participant who received standard transfusions. 23 severe adverse events in nine (15%) patients were reported for hydroxycarbamide and ten serious adverse events in six (10%) patients were reported for standard transfusions. The most common serious adverse event in both groups was vaso-occlusive pain (11 events in five [8%] patients with hydroxycarbamide and three events in one [2%] patient for transfusions). INTERPRETATION: For high-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocities and help to prevent primary stroke. FUNDING: National Heart, Lung, and Blood Institute, National Institutes of Health.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/26670617

dc.identifier

S0140-6736(15)01041-7

dc.identifier.eissn

1474-547X

dc.identifier.uri

https://hdl.handle.net/10161/16031

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Lancet

dc.relation.isversionof

10.1016/S0140-6736(15)01041-7

dc.subject

Adolescent

dc.subject

Anemia, Sickle Cell

dc.subject

Antisickling Agents

dc.subject

Blood Flow Velocity

dc.subject

Blood Transfusion

dc.subject

Cerebrovascular Circulation

dc.subject

Child

dc.subject

Child, Preschool

dc.subject

Combined Modality Therapy

dc.subject

Drug Substitution

dc.subject

Female

dc.subject

Humans

dc.subject

Hydroxyurea

dc.subject

Male

dc.subject

Stroke

dc.subject

Treatment Outcome

dc.subject

Ultrasonography, Doppler, Transcranial

dc.title

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

dc.type

Journal article

duke.contributor.orcid

Rothman, Jennifer A|0000-0003-1582-2886

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/26670617

pubs.begin-page

661

pubs.end-page

670

pubs.issue

10019

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Hematology

pubs.organisational-group

Pediatrics

pubs.organisational-group

Pediatrics, Hematology-Oncology

pubs.organisational-group

Psychiatry, Child & Family Mental Health and Developmental Neuroscience

pubs.organisational-group

Psychiatry & Behavioral Sciences

pubs.organisational-group

Psychology and Neuroscience

pubs.organisational-group

School of Medicine

pubs.organisational-group

Surgery

pubs.organisational-group

Trinity College of Arts & Sciences

pubs.publication-status

Published

pubs.volume

387

Files